Daguang Wang
Directeur/Membre du Conseil chez Metabomed Ltd.
Profil
Daguang is the managing director of Yonjin Venture, the North America and Europe investment arm of Yongjin Group in Shanghai, China.
Before venture investment, Daguang spent more than 20 years in the biotech and pharmaceutical industry with Amgen, Memory Pharmaceuticals, PsychoGenics, EMD Serono and Sanofi.
Daguang started his career as a scientist in neuroscience, working in the areas of neurodegenerative diseases and psychiatric disorders, before moving to business development and external innovation with a focus on neuroscience, multiple sclerosis and rare diseases.
Daguang was a global lead of business development and external innovation for neuroscience at Sanofi before joining Yonjin Venture in 2018.
Daguang serves on the board of multiple biotech companies.
Daguang received his bachelor degree in biochemistry from Jilin University in China, and his PhD in molecular genetics from the Washington University in St Louis in the US.
Daguang conducted postdoctoral research at Stanford University with Professor Roger Kornberg.
Postes actifs de Daguang Wang
| Sociétés | Poste | Début |
|---|---|---|
Metabomed Ltd.
 Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Directeur/Membre du Conseil | - |
Ultivue, Inc.
 Ultivue, Inc. BiotechnologyHealth Technology Ultivue, Inc. engages in provision of biotechnology services. It offers super-resolution imaging, single-molecule and diagnostics services. Its product Multiplex IHC Reagent Kits, a performance marker multiplexing detection and analysis.The company was founded by Peng Yin, David Walt and Ralf Jumgmann in 2015 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Yonjin Venture LLC
 Yonjin Venture LLC Investment ManagersFinance Yonjin Venture LLC (Yonjin Venture) is a venture capital subsidiary of Yongjin Group, Inc. founded in 2018. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 01/06/2018 |
Anciens postes connus de Daguang Wang
| Sociétés | Poste | Fin |
|---|---|---|
Sanofi, Inc. (China)
 Sanofi, Inc. (China) Pharmaceuticals: MajorHealth Technology Part of Sanofi, Inc. (China) is a Chinese company that manufactures pharmaceutical products for heart, kidney, and diabetes problems. The company is based in Shanghai, China. | Private Equity Investor | 30/07/2018 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Private Equity Investor | 31/03/2015 |
OncoResponse, Inc.
 OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Directeur/Membre du Conseil | - |
Formation de Daguang Wang
| Jilin University | Undergraduate Degree |
| Washington University School of Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Health Technology |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Health Technology |
Ultivue, Inc.
Ultivue, Inc. BiotechnologyHealth Technology Ultivue, Inc. engages in provision of biotechnology services. It offers super-resolution imaging, single-molecule and diagnostics services. Its product Multiplex IHC Reagent Kits, a performance marker multiplexing detection and analysis.The company was founded by Peng Yin, David Walt and Ralf Jumgmann in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Yonjin Venture LLC
Yonjin Venture LLC Investment ManagersFinance Yonjin Venture LLC (Yonjin Venture) is a venture capital subsidiary of Yongjin Group, Inc. founded in 2018. The firm is headquartered in Cambridge, Massachusetts. | Finance |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Sanofi, Inc. (China)
Sanofi, Inc. (China) Pharmaceuticals: MajorHealth Technology Part of Sanofi, Inc. (China) is a Chinese company that manufactures pharmaceutical products for heart, kidney, and diabetes problems. The company is based in Shanghai, China. | Health Technology |
